Exozymes grants director Lalonde 10,000 stock options

The options expire on October 1, 2033, under the terms of the award.

Rhea-AI Filing Summary

Exozymes Inc. director James Joseph Lalonde received a grant of 10,000 stock options to buy common stock on October 1, 2026, with an exercise price of $6.28 per share. The options vest in 12 quarterly installments: 11 installments of 833 shares and a final installment of 837 shares, beginning December 31, 2026, and ending September 30, 2029, subject to the reporting person's continued service with the issuer.

Insider Trade Summary

Grant/Award: 10,000 shares

Grant/Award 1 txn

Insider Lalonde James Joseph

Role Director

Type	Security	Shares	Price	Value
Grant/Award	Stock Option (right to buy) F1	10,000	$0.00	$0.00

Holdings After Transaction: Stock Option (right to buy) — 10,000 contracts (Direct)

Footnotes (1)

1. F1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 833 shares and a final installment of 837 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.

Key Figures

Stock options granted: 10,000 options Exercise price: $6.28 per share Vesting installments: 12 quarterly installments +4 more

7 metrics

Stock options granted 10,000 options Grant dated October 1, 2026

Exercise price $6.28 per share Price to exercise the options

Vesting installments 12 quarterly installments Beginning December 31, 2026

Regular installment 833 shares Each of 11 installments

Final installment 837 shares Final vesting installment

Vesting schedule end September 30, 2029 End of the stated vesting schedule

Expiration date October 1, 2033 Option expiration

Key Terms

Stock Option (right to buy), quarterly installments, exercise price, continued service

4 terms

Stock Option (right to buy) financial

"Stock Option (right to buy)"

quarterly installments financial

"twelve (12) quarterly installments"

exercise price financial

"at an exercise price of $6.2800"

The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.

continued service financial

"subject to the reporting person's continued service with the issuer"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EXOZ options did James Joseph Lalonde receive, and at what exercise price?

Director James Joseph Lalonde received 10,000 stock options to buy Exozymes Inc. common stock, with an exercise price of $6.28 per share. The grant was dated October 1, 2026.

When do James Joseph Lalonde's EXOZ options expire?

They expire on October 1, 2033.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/19/2026 - 07:47 PM EDT Accepted by SEC EDGAR 10/19/2026 - 07:47 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lalonde James Joseph

(Last) (First) (Middle)

C/O 750 ROYAL OAKS DRIVE, SUITE 106

(Street)

MONROVIA CALIFORNIA 91016

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
EXOZYMES INC. [ EXOZ ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
10/01/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Stock Option (right to buy)	$6.28	10/01/2026		A		10,000		(1)	10/01/2033	Common Stock	10,000	$0.00	10,000	D

Explanation of Responses:

1. The option vests in twelve (12) quarterly installments, consisting of eleven (11) installments of 833 shares and a final installment of 837 shares, beginning on 12/31/2026 and ending on 09/30/2029, subject to the reporting person's continued service with the issuer. The option expires on 10/01/2033.

	/s/ James J. Lalonde	10/19/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)